化疗联合中药治疗晚期原发性肝癌的观察

Analyses of clinical treatment results with different remedies in advanced primary liver cancer

回顾分析70例晚期肝癌患者不同治疗方案及毒副反应等。结果消癌平+氟尿脱氧核苷+顺铂(A组)总有效率为31.82%,艾迪+羟基喜树碱(B组)和多柔比星+顺铂+5氟尿嘧啶(C组)分别为11.11%和13.33%,差异无统计学意义,P=0.175。中位生存期,A组为18个月,B、C组分别为6和8个月,差异有统计学意义,P=0.022。临床症状改善(肝痛、腹胀、腹水、食欲减退和疲乏等)A组比B、C组明显,毒副反应A组比B、C组发生率低。初步研究结果提示,中药配合西药化疗的综合治疗具有临床应用的意义。

The efficacy and toxicity of different remedies in 70 cases of advanced primary liver cancer were reviewed and analysised. Results total efficiencies were 31.82%, 11.11% and 13.33% in group A （xiaoaipine＋doxifluridine＋cisplation）, group B （ Aidi＋ hydroxycamptothecine） and group C （ doxorubicin＋ cisplatin＋ fluorouracil） respectively, and there were no differences, P=0.175. The median survival time were 18 months, 6 months and 8 months in group A, group B and group C respectively, and there were significant differences, P= 0. 022. The improvement index of clinical symptoms （hepatalgia, ascites, abdominal dissension, poor appetite and fatigue） was more significant in group A than those in group B and C. Side effect was lower in group A than those in group B and C. So traditional Chinese medicine combined with Western medicine plays an important role in clinical application.